• Thirty patients with severe pustulosis palmoplantaris completed a placebo-controlled comparative trial. Patients were randomly allocated to placebo or etretinate therapy; after two weeks, psoralen plus long-wave ultraviolet light (PUVA) treatment was instituted on one hand or foot, while the other hand or foot served as an untreated control. Fourteen of 18 hands or feet cleared with the combined treatment, compared with three of 18 with etretinate treatment and three of 12 with PUVA treatment. Follow-up showed a high relapse rate. Treatment of severe pustulosis palmoplantaris must be individualized to minimize short- and long-term side effects.
(Arch Dermatol 1987;123:885-889)
Rosén K, Mobacken H, Swanbeck G. PUVA, Etretinate, and PUVA-Etretinate Therapy for Pustulosis Palmoplantaris: A Placebo-Controlled Comparative Trial. Arch Dermatol. 1987;123(7):885–889. doi:10.1001/archderm.1987.01660310053013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.